Observational studyMedicine2026
Efficacy of omeprazole combined with endoscopic hemostasis in the treatment of patients with bleeding peptic ulcers.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bleeding peptic ulcers remain a major cause of non-variceal upper gastrointestinal hemorrhage, and optimizing post-endoscopic pharmacologic therapy is essential to reducing early rebleeding and improving clinical outcomes. This study evaluated the therapeutic effectiveness of high-dose versus low-dose omeprazole following endoscopic hemostasis. This retrospective observational study included patients with endoscopically confirmed bleeding peptic ulcers treated between August 2022 and August 2025. Patients received either high-dose omeprazole (80-mg intravenous loading dose followed by continuous infusion at 4 mg/h) or low-dose omeprazole (40 mg intravenously once daily) after endoscopic hemostasis. Hemoglobin, hematocrit, rebleeding rates, clinical recovery parameters, and adverse events were collected. Participants were followed for 30 days to evaluate delayed rebleeding. Continuous variables were analyzed using independent-samples t tests, and categorical variables using chi-square tests. A total of 119 patients were included (high-dose: n = 58; low-dose: n = 61). High-dose omeprazole significantly reduced rebleeding at 72 hours (6.9% vs 21.3%, P = .025) and 30 days (10.3% vs 29.5%, P = .009). Greater increases in hemoglobin and hematocrit, lower transfusion volume, faster cessation of bleeding, earlier hemodynamic stabilization, and shorter hospitalization were also observed (all P < .001). Adverse event rates were comparable between groups. High-dose omeprazole combined with endoscopic hemostasis enhances hemostatic stability, accelerates clinical recovery, and reduces short-term rebleeding without increasing treatment-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.